We are live on
!
Find out more
TA
Tamarack Advisers Portfolio holdings
AUM
$2.12M
1-Year Est. Return
58.09%
This Fund
S&P 500
This Quarter
Est. Return
+8.42%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$353M
AUM Growth
-$134M
(-28%)
Cap. Flow
-$160M
Cap. Flow
% of AUM
-45.25%
Top 10 Holdings %
Top 10 Hldgs %
53.01%
Holding
85
New
13
Increased
11
Reduced
25
Closed
34
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Henry Schein
HSIC
|
+$15.5M |
| 2 |
Cigna
CI
|
+$8.74M |
| 3 |
AdaptHealth
AHCO
|
+$8.55M |
| 4 |
Viatris
VTRS
|
+$8.32M |
| 5 |
UnitedHealth
UNH
|
+$7.97M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Labcorp
LH
|
+$19.6M |
| 2 |
HOLX
Hologic
HOLX
|
+$18.4M |
| 3 |
Quest Diagnostics
DGX
|
+$17.7M |
| 4 |
LMNX
Luminex Corp
LMNX
|
+$15.3M |
| 5 |
RadNet
RDNT
|
+$12.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 86.67% |
| 2 | Consumer Staples | 5.19% |
| 3 | Consumer Discretionary | 1.58% |
| 4 | Technology | 0.36% |
| 5 | Energy | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Xeris Biopharma Holdings
XERS
$1.45B
| – | – |
-350,000
| Closed | -$1.58M |
|
77
CALL
State Street Materials Select Sector SPDR ETF
XLB
$8.72B
| – | – |
-200
| Closed | -$94K |
|
78
CALL
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
$21.7B
| – | – |
-100
| Closed | -$90K |
|
79
PUT
State Street SPDR NYSE Technology ETF
XNTK
$1.94B
| – | – |
-1,000
| Closed | -$643K |
|
|
CTLT
80
PUT
DELISTED
CATALENT, INC.
CTLT
| – | – |
-250
| Closed | -$363K |
|
|
HMHC
81
DELISTED
Houghton Mifflin Harcourt Company
HMHC
| – | – |
-20,000
| Closed | -$152K |
|
|
NUAN
82
DELISTED
Nuance Communications, Inc.
NUAN
| – | – |
-225,000
| Closed | -$9.82M |
|
|
LMNX
83
DELISTED
Luminex Corp
LMNX
| – | – |
-478,327
| Closed | -$15.3M |
|
Similar funds
SCM
LBC
ICM
LCMP
GIP
STC
GC
DU
Tamarack Advisers's Q2 2021 Portfolio in Review
As of Q2 2021, Tamarack Advisers held 85 positions worth $353M, down 28% from $488M the previous quarter. Its ten largest holdings account for 53% of the portfolio.
Tamarack Advisers withdrew a net $160M in Q2 2021, closing 34 positions and reducing 25 holdings. Its most notable exit was Hologic, an estimated $18.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 85% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.
Against the trend, Tamarack Advisers opened a new position in Cigna worth $8.3M.
- Tamarack Advisers's largest Q2 2021 buy was Cigna: 35,000 shares worth $8.3M.
- Tamarack Advisers added most to Henry Schein in Q2 2021, an estimated $15.5M increase.
- Tamarack Advisers's biggest Q2 2021 reduction was Labcorp, cutting an estimated $19.6M.
- Tamarack Advisers fully exited Hologic in Q2 2021, selling an estimated $18.4M.
- Tamarack Advisers's ten largest holdings make up 53% of its $353M portfolio in Q2 2021.
- Tamarack Advisers opened 13 new positions and closed 34 in Q2 2021.
- Tamarack Advisers's portfolio value fell 28% quarter-over-quarter to $353M.
Based on Tamarack Advisers's 13F filing for Q2 2021, filed 13 Aug 2021.